Analysis of inflammation- and atherosclerosis-related gene polymorphisms in branch retinal vein occlusion

Iris Steinbrugger,1 Anton Haas,1 Richard Maier,1 Wilfried Renner,2 Monika Mayer,1 Christoph Werner,1 Andreas Wedrich,1 Yosuf El-Shabrawi,1 Otto Schmut,1 Martin Weger1

1Department of Ophthalmology, Medical University of Graz, Graz, Austria; 2Clinical Institute of Medical and Chemical Laboratory Diagnostics, Medical University of Graz, Graz, Austria

Purpose: Branch retinal vein occlusion (BRVO) is a common vision-threatening disease. Compression of the underlying retinal vein due to increased rigidity of the crossing artery has been implicated in the pathogenesis of BRVO. Among others, arterial hypertension and hypercholesterolemia, both of which contribute to atherogenesis, have been identified as risk factors. Atherosclerosis itself is a chronic low-grade inflammatory disease with a distinct pro-inflammatory cytokine pattern. In addition to its role in atherogenesis, some cytokines have been shown to exert procoagulatory effects, and may thus contribute to the development of BRVO by a second mechanism. Gene polymorphisms affecting the expression of inflammation-related cytokines are therefore considered as potential risk factors for BRVO. The purpose of the present study was to investigate hypothesized associations between cytokine gene polymorphisms and the presence of BRVO.

Methods: The study comprised 398 patients with BRVO and 355 control subjects. Using 5’exonuclease assays (TaqMan), genotypes of the following functional single nucleotide polymorphisms were determined: interleukin 1 beta (IL1B) −511C>T, interleukin 1 receptor antagonist (IL1RN) 1018T>C, interleukin 4 (IL4) −584C>T, interleukin 6 (IL6) −174G>C, interleukin 8 (IL8) −251A>T, interleukin 10 (IL10) −592C>A, interleukin 18 (IL18) 183A>G, tumor necrosis factor (TNF) −308G>A, monocyte chemotactic protein 1 (MCP-1) −2518A>G, and RANTES (CCL5) −403G>A.

Results: Neither genotype distributions nor allele frequencies of any of the investigated polymorphisms differed significantly between BRVO patients and controls (p>0.05). Arterial hypertension was found to be significantly more prevalent in BRVO patients than in controls (p<0.001). In a logistic regression analysis presence of arterial hypertension was associated with an odds ratio of 3.33 (95% confidence interval: 2.42–4.57) for BRVO.

Conclusions: As none of the investigated gene variants was significantly more prevalent in BRVO patients than among control subjects, our data suggest that these polymorphisms themselves are unlikely major risk factors for BRVO.

Branch retinal vein occlusion (BRVO) is a vision-threatening disease, commonly affecting patients older than 60 years. It frequently occurs at an arteriovenous crossing site, where the retinal vein shares a common adventitial sheath with the retinal artery [1,2]. Increased rigidity of the crossing artery resulting from atherosclerotic disease has been suggested to cause compression of the underlying vein, resulting in turbulent blood flow, endothelial damage, and thrombus formation [3]. Consequently, arterial hypertension, elevated plasma homocysteine concentrations, and hypercholesterolemia, all of which are known to contribute to atherogenesis, have been identified as BRVO risk factors [4-7].

Atherosclerosis itself is a chronic low-grade inflammatory disease, which is characterized by the recruitment of both monocytes and T lymphocytes to the site of inflammation and a distinct pro-inflammatory T_{H1} cytokine pattern [8,9]. Animal experiments have provided some evidence that a lack of anti-inflammatory cytokines promotes atherogenesis, whereas deficiency of pro-inflammatory cytokines is associated with reduced atherogenesis [10-12]. Importantly, cytokines and chemokines such as interleukin 1 beta (IL-1β), interleukin 6 (IL-6), interleukin 8 (IL-8), tumor necrosis factor alpha (TNF-α), and monocyte chemotactic protein 1 (MCP-1) have also been reported to affect hemostasis, and may thus contribute to thrombus formation [13-17].

Single nucleotide polymorphisms (SNPs) affecting the expression of cytokines or chemokines previously implicated in atherogenesis as well as activation of the coagulation cascade are thus potential risk factors for BRVO. Nevertheless, they have not yet been investigated among BRVO patients. Consequently, in the present study, functional gene polymorphisms encoding the following cytokines or chemokines were chosen as candidate risk factors:

- The pro-inflammatory cytokine IL-1β exerts strong pro-atherogenic effects by enhancing expression of intercellular adhesion molecule 1 (ICAM-1) and vascular cell adhesion molecule 1 (VCAM-1) on endothelial cells. Furthermore, IL-1β induces the synthesis of chemokines, such as IL-8 and MCP-1, and thus facilitates the transendothelial migration of
inflammatory cells [18,19]. Additional evidence for its role in atherosclerosis comes from an animal model showing that in apoE-deficient mice a lack of IL-1β is associated with decreased severity of atherosclerosis [20]. IL-1β also exerts procoagulatory effects by increasing the expression of tissue factor, which itself plays an essential role in the activation of the extrinsic pathway of the coagulation cascade [13]. Furthermore, increased expression of IL-1β downregulates tissue-type plasminogen activator (t-PA), and thus impairs fibrinolysis [21]. A gene polymorphism, characterized by a C to T transition at position –511 of the fibrinolysis [21]. A gene polymorphism, characterized by a C to T transition at position –511 of the tissue–type plasminogen activator (t-PA), and thus impairs the extrinsic pathway of the coagulation cascade [13].

Fishman and coworkers identified a functional gene polymorphism in the promoter region of the IL6 gene, which is characterized by a C to T substitution at position –174 (IL6–174G>C, rs1800795). Using transfected HeLa cells, Fishman and colleagues found higher baseline IL-6 levels in cells with the G construct compared to those transfected with the C allele. Stimulation with LPS or IL-1 resulted in a significantly increased IL-6 transcription rate among cells carrying the G allele [40]. Another study using anti CD3/CD28-stimulated peripheral blood lymphocytes found three times higher IL-6 concentrations among carriers of the G allele [41]. Interestingly, the IL6–174G>C polymorphism has previously been suggested to affect susceptibility to retinal artery occlusion (RAO). Its role in BRVO, however, still remains elusive [42].

In contrast to IL-6, interleukin 10 (IL-10) is an anti-inflammatory T₃₁₂-associated cytokine that mediates anti-atherogenic pathways by suppressing the synthesis of several pro-inflammatory cytokines such as IL-1β, IL-6, interleukin 12 (IL-12), TFN-α, and interferon-gamma (IFN-γ) [43]. Its protective role in atherogenesis has also been confirmed by animal experiments [12]. As for hemostasis, IL-10 has been shown to inhibit LPS induced tissue factor expression in monocytes [44]. Gene polymorphisms are thought to account for up to 75% of the variability of IL-10 production [45], and increased IL-10 expression has been associated with the presence of a TCATA haplotype formed by polymorphisms at position -3575, -2763, -1082, -819, and -592 in the promoter region of the IL10 gene [46,47]. Due to strong linkage disequilibrium, the presence of this haplotype can be fully determined by analysis of the IL10−592C>A polymorphism (rs1800872). The IL10−592A allele indicates the presence of the presumed anti-inflammatory TCATA haplotype, while the −592C allele indicates its absence. As for retinal vascular diseases, an association between the IL10−592C>A polymorphism and RAO risk has been reported [48].

Animal models have also provided evidence that the pro-inflammatory cytokine interleukin 18 (IL-18) contributes to the development of atherosclerosis. In synergy with IL-12, IL-18 promotes the Th1 immune response by inducing the IFN-γ synthesis [19]. It also upregulates the synthesis of pro-inflammatory cytokines such as IL-1β and IL-8 as well as the expression of adhesion molecules [49]. In apoE knockout mice, administration of IL-18 has been associated with enhancement of atherosclerosis, whereas deficiency of IL-18 has been shown to reduce the extent of atherosclerosis [50, 51]. IL-18 expression has been found to be decreased among carriers of the GCAGT haplotype formed by polymorphisms at position -887, -105, +105, +183, and +533 in the promoter and 5′untranslated region of the IL18 gene [52]. By analysis of the IL18+183A>G polymorphism (rs5744292) the GCAGT haplotype can be identified, since this haplotype is the only one including the +183G allele. Thus, the IL18+183G
Allele indicates the presence of this haplotype, while the +183A allele indicates its absence.

Overexpression of TNF-α, a potent pro-inflammatory cytokine mainly produced by macrophages and T cells, has also been implicated in the pathogenesis of atherosclerosis [19]. TNF-α upregulates both the expression of adhesion molecules (ICAM-1, VCAM-1) and chemokines such as MCP-1, thereby facilitating the recruitment of monocytes to atherosclerotic lesions [53]. In apoE-deficient mice a lack of TNF-α was observed to be associated with a reduced size of atherosclerotic lesions [54]. TNF-α also exerts procoagulatory effects by upregulating tissue factor expression and by inhibition of the thrombomodulin/protein C anticoagulation pathway [14,15]. In addition, impairment of fibrinolysis is caused by TNF-α induced t-PA downregulation [55].

A TNF promoter polymorphism, which is caused by a G to A substitution at position −308 of the TNF gene (TNF-308G>A, rs1800629), has been reported to modulate the expression of TNF-α. The presence of the TNF-308A allele has been found to be associated with higher constitutive and inducible TNF-α levels after LPS stimulation compared to the −308GG genotype [56].

Importantly, the migration of leukocytes to the site of inflammation occurs along a gradient of various chemokines including MCP-1, IL-8, and RANTES (regulated on activation, normal T cell expressed and secreted). MCP-1 belongs to the CC family of chemokines, and its expression

| Polymorphism | Primer/probe | Sequence |
|--------------|--------------|----------|
| **IL1B** -511C>T (rs16944) | forward primer | GAGGCTCTGCAATTGACAGA |
| reverse primer | TCTCTACCTGGTGCTTCT |
| C probe | VIC-CTGCTCTGGAGCT-NFQ |
| T probe | FAM-CTGCTCTAGAGCT-NFQ |
| **IL1RN** 1018T>C (rs4251961) | forward primer | CGCGTACACCTAAGTCTAGTAG |
| reverse primer | GCCCTTGACACTTATTTTGACA |
| T probe | VIC-AAAACTGGACCTGATGAT-NFQ |
| C probe | FAM-AATGGACCTTGCTAGAT-NFQ |
| **IL4** -584C>T (rs2243350) | forward primer | GACCTGCTCCTCTCAAAACACCTAA |
| reverse primer | GGCAGAATAAAGAGCAGCAGATCT |
| C probe | VIC-ATTGTCCTCCAGTGCT-NFQ |
| T probe | FAM-ATGTTCTCCAGTGCT-NFQ |
| **IL6** -174G>C (rs1800795) | forward primer | GAGCACCTAAAGCTGCACCTTTCC |
| reverse primer | GCGCTGATTGAAACCTTATAGTG |
| C probe | VIC-CCTTTCAGCATGCAAGAC-NFQ |
| **IL10** -592C>A (rs1800872) | forward primer | GCTAAAGGAGCTGGAACACATC |
| reverse primer | GCCCTCTCATTTTCTTTCCAGAGA |
| C probe | VIC-CGGCGCTGCTCTTATG-NFQ |
| A probe | FAM-CGCGCTGTACCTTAG-NFQ |
| **IL18** +183A>G (rs5744292) | forward primer | AGCTGAGTGTAGTAGCGACATG |
| reverse primer | CTCTCTAGCTCCAGCTTTG |
| A probe | VIC-CTCTACTCCCCAGCTA-NFQ |
| G probe | FAM-CTCTACTCCCCCGCT-NFQ |
| **TNF** -308G>A (rs1800629) | forward primer | CCAAAAGAAATGGAGGCAATAGGTT |
| reverse primer | GAGGCTGAGGCTGACACAG |
| G probe | VIC-CCTCGCTCACGTATCTC-NFQ |
| A probe | FAM-CCTCGCTACGTCTC-NFQ |
| **CCL2** -2518A>G (rs1024611) | forward primer | GGAGGGCATCTTTTCTTGAGA |
| reverse primer | GAAAGGTAAGGGGTATGATCATGAA |
| A probe | VIC-AGACAGCGCTATACCT-NFQ |
| G probe | FAM-AGACAGCTGGTCCTTT-NFQ |
| **IL8** -251A>T (rs4073) | Assay-on-demand | Predesigned assay from Applied Biosystems; primer and probe sequences not available. |
| (C_11748116_10) | | |
| **CCL5** -403G>A (rs2107538) | forward primer | ACTGAGTCTTAAAGGTTCCTGCTT |
| reverse primer | GAGGACCTCTCCATATACACCTTATAAAAT |
| A probe | VIC-CATTACAGATCTTTCACTTAT-NFQ |
| G probe | FAM-CATTACAGATCTTTCACTTAT-NFQ |

Sequences of primers and probes for TaqMan genotyping assays are presented. FAM and VIC are names of fluorescent dyes. NFQ is the abbreviation for non-fluorescent quencher.
in both endothelial cells and monocytes can be induced by pro-inflammatory cytokines such as IL-1, IFN-γ, and TNF-α [57]. A large body of evidence indicates that MCP-1 plays an essential role in atherogenesis by recruiting monocytes and macrophages to atherosclerotic lesions [58,59]. MCP-1 has also been reported to have a procoagulant function by inducing tissue factor expression [60]. An A to G substitution at position −2518 of the MCP-1 gene (CCL2−2518A>G, rs1024611) has been noted to affect MCP-1 expression [61]. After IL-1β stimulation, peripheral blood mononuclear cells from individuals carrying the −2518G allele showed a significantly higher MCP-1 synthesis than cells from individuals homozygous for the −2518A allele [61].

Endothelial secretion of IL-8, a member of the CXC chemokine family, is induced by pro-inflammatory cytokines such as IL-1 and TNF-α [62]. IL-8 is a potent chemoattractant for neutrophils, and, like MCP-1, also triggers firm adhesion of rolling monocytes to the vascular endothelium, thus contributing to the development of atherosclerotic lesions [63]. Decreased susceptibility to atherosclerosis has been demonstrated in mice lacking the IL-8 receptor [64]. IL-8 has also been shown to increase the expression of tissue factor in monocytes [13]. Hull and coworkers [65] identified a common SNP in the promoter region of the IL8 gene, which is caused by an A to T substitution at position −251 (IL8−251A>T, rs4073). The IL8−251T allele was found to be associated with a two- to fivefold stronger luciferase expression than the −251A allele, suggesting a pro-inflammatory effect in carriers of this allele [66].

Finally, RANTES, a member of the CC family of chemokines, is produced by T lymphocytes and monocytes. As a potent chemoattractant, RANTES has been shown to trigger monocyte arrest on dysfunctional endothelium [67]. Furthermore, RANTES is expressed by T cells in advanced atherosclerotic lesions [68]. In a hypercholesterolemic mouse model, administration of the CC chemokine antagonist Met-RANTES resulted in reduced atherosclerotic lesion sizes [69]. A SNP in the promoter region of the RANTES gene (CCL5), which is caused by a G to A substitution at position -403 (CCL5−403G>A, rs2107538) has been identified [70]. In cells transfected with the −403A variant, increased transcriptional activity has been demonstrated.

So far none of these functional gene polymorphisms has been studied as a potential risk factor for BRVO. The purpose of the present study was thus to investigate a hypothesized association between the aforementioned gene polymorphisms and the presence of BRVO.

METHODS

The present study enrolled 398 patients with BRVO (228 females and 170 males) and 355 control subjects (206 females and 149 males). The mean age of patients was 67.1±11.0 years (range: 37–93 years) and 68.3±13.8 years (range: 21–93 years) in the control group. All participants were of Caucasian origin, living in the same geographical area and were seen at the local Department of Ophthalmology, Medical University of Graz. The study was approved by the Institutional Review Board of the Medical University of Graz and followed the principles of the Declaration of Helsinki. Prior to enrollment, written informed consent was obtained from all participants. Diagnosis of BRVO was made if fundus examination revealed venous dilation and tortuosity with intraretinal hemorrhages in a wedge-shaped region, with the apex of the wedge pointing to an arteriovenous crossing point.

The control group was hospital-based and comprised patients seen at the Department of Ophthalmology, Medical University of Graz for reasons other than retinal vascular occlusion, such as cataract or glaucoma surgery. All controls underwent a detailed fundus examination. Excluded as controls were patients who had a history of retinal vascular occlusions, deep vein thrombosis, pulmonary embolism, myocardial infarction, or stroke.

Arterial hypertension was defined by a systolic blood pressure ≥140 mmHg, a diastolic blood pressure of ≥90 mmHg, or the intake of antihypertensive drugs. Participants were classified as diabetics if they were being treated for insulin or non-insulin-dependent diabetes mellitus. Hypercholesterolemia was defined by fasting plasma

| Clinical characteristics                      | BRVO patients (n=398) | Control subjects (n=355) | p-value |
|----------------------------------------------|-----------------------|--------------------------|---------|
| Females                                      | 228 (57.3%)           | 206 (58.0%)              | 0.84    |
| Mean age (years±SD)                          | 67.1±11.0             | 68.3±13.8                | 0.18    |
| Arterial hypertension                        | 306 (76.9%)           | 183 (51.5%)              | <0.001  |
| Diabetes mellitus                            | 27 (6.8%)             | 24 (6.8%)                | 0.99    |
| Hypercholesterolemia                         | 310 (77.9%)           | 260 (73.2%)              | 0.14    |
| Ever-smoker                                  | 119 (29.9%)           | 90 (25.4%)               | 0.16    |

Prevalence of arterial hypertension was significantly higher in branch retinal vein occlusion (BRVO) patients compared to control subjects. Data are mean±standard deviation, or number of subjects (%).
cholesterol levels above 200 mg/dl or the intake of lipid-lowering drugs. Participants were classified as either ever (current/previous) smokers or nonsmokers. A standardized questionnaire was employed to obtain data on medication intake as well as history of deep vein thrombosis, pulmonary embolism, myocardial infarction, and stroke.

Candidate gene polymorphisms were selected using the following criteria: association of the polymorphism with gene expression or activity of the gene product; involvement of the gene product in pro- or anti-inflammatory pathways; a minor allele frequency of 5% or higher; and no data available on the role of this gene variant in BRVO. Genomic DNA was isolated from whole blood by standard methods (QIA-AMP DNA, blood mini kit, Qiagen, Vienna, Austria) and stored at −20 °C. Genotypes of the aforedescribed polymorphisms were determined by 5′ exonuclease assays (TaqMan). Applied Biosystems Assay-by-Design custom service (Applied Biosystems, Vienna, Austria) was used for design and manufacture of primer and probe sets. Sequences of primers and probes are presented in Table 1. Endpoint fluorescence data were exported into Excel format and analyzed as scatter plots. Samples were analyzed in batches, each containing 94 samples and 2 negative controls (water instead of DNA). Next, 50 samples were reanalyzed, and the results were identical for all samples.

Statistics: SPSS for windows (release 15.0.1; SPSS, Inc., Chicago, IL) was used for statistical analyses. Continuous variables were analyzed by Student’s t-test and presented as means±SD. Categorial variables were presented as percentages and were compared by the χ² test. Odds ratios and 95% confidence intervals (CI) were calculated by logistic regression analysis, and genotypes were coded assuming an allele dose effect (wildtype genotype=0, heterozygous carrier

| Table 3. Genotype and allele frequencies in patients with branch retinal vein occlusion and control subjects. |
|---------------------------------------------------------------|
| **Polymorphism** | **Genotype** | **BRVO patients** | **Control subjects** | **p-value** |
| IL1B -511C>T (rs16944) | CC | 183 (46.0%) | 162 (45.6%) | 0.68 |
| | CT | 184 (46.2%) | 159 (44.8%) |
| | TT | 31 (7.8%) | 34 (9.6%) |
| T allele frequency | 0.309 | 0.32 | 0.66 |
| IL1RN 1018T>C (rs4251961) | TT | 140 (35.2%) | 145 (40.8%) | 0.15 |
| | TC | 210 (52.8%) | 162 (45.6%) |
| | CC | 48 (12.1%) | 48 (13.5%) |
| C allele frequency | 0.384 | 0.363 | 0.4 |
| IL4 -584C>T (rs2243250) | CC | 287 (72.1%) | 253 (71.3%) | 0.58 |
| | CT | 106 (26.6%) | 94 (26.5%) |
| | TT | 5 (1.3%) | 8 (2.3%) |
| T allele frequency | 0.146 | 0.155 | 0.62 |
| IL6 -174G>C (rs1800795) | GG | 130 (32.7%) | 115 (32.4%) | 0.97 |
| | GC | 197 (49.5%) | 174 (49.0%) |
| | CC | 71 (17.8%) | 66 (18.6%) |
| C allele frequency | 0.426 | 0.431 | 0.84 |
| IL10 -592C>A (rs1800872) | CC | 216 (54.3%) | 186 (52.4%) | 0.14 |
| | CA | 161 (40.5%) | 137 (38.6%) |
| | AA | 21 (5.3%) | 32 (9.0%) |
| A allele frequency | 0.255 | 0.283 | 0.22 |
| IL18 +183A>G (rs5744292) | AA | 232 (58.3%) | 204 (57.5%) | 0.11 |
| | AG | 154 (38.7%) | 129 (36.3%) |
| | GG | 12 (3.0%) | 22 (6.2%) |
| G allele frequency | 0.224 | 0.244 | 0.36 |
| TNF -308G>A (rs1800629) | GG | 277 (69.6%) | 251 (70.7%) | 0.95 |
| | GA | 115 (28.9%) | 99 (27.9%) |
| | AA | 6 (1.5%) | 5 (1.4%) |
| A allele frequency | 0.16 | 0.154 | 0.75 |
| CCL2 -2518A>G (rs1024611) | AA | 225 (56.5%) | 206 (58.0%) | 0.48 |
| | AG | 147 (36.9%) | 133 (37.5%) |
| | GG | 26 (6.5%) | 16 (4.5%) |
| G allele frequency | 0.25 | 0.232 | 0.43 |
| IL8 -251A>T (rs4073) | AA | 76 (19.1%) | 82 (23.1%) | 0.23 |
| | AT | 215 (54.0%) | 171 (48.2%) |
| | TT | 107 (26.9%) | 102 (27.8%) |
| T allele frequency | 0.539 | 0.528 | 0.68 |
| CCL5 -403G>A (rs2107538) | GG | 272 (68.3%) | 235 (66.2%) | 0.63 |
| | GA | 113 (28.4%) | 104 (29.3%) |
| | AA | 13 (3.3%) | 16 (4.5%) |
| A allele frequency | 0.175 | 0.192 | 0.4 |

Genotype and allele frequencies were not significantly different between branch retinal vein occlusion (BRVO) patients and control subjects, suggesting that these genotypes are not associated with BRVO risk.
of the mutated allele=1, homozygous carrier for the mutated allele=2). A p<0.05 was considered statistically significant.

RESULTS
Clinical characteristics of both groups are shown in Table 2. Arterial hypertension was significantly more prevalent in BRVO patients than among control subjects (76.9% versus 51.5%; p<0.001). Hypercholesterolemia and ever-smoking status were also higher among patients than in the control group; however neither characteristics were statistically significant (Table 2).

Table 3 presents genotype distributions and allele frequencies in BRVO patients and controls. Neither allele frequencies nor genotype distributions of any of the investigated gene polymorphisms were found to be significantly different between patients and controls. Observed genotype distributions were in line with those predicted by the Hardy–Weinberg equilibrium, and allele frequencies among controls were similar to those previously observed among other Caucasian populations [22,25,52,71-77]. In a logistic regression analysis, presence of BRVO was predicted by arterial hypertension, but not by any of the ten investigated gene polymorphisms (Table 4).

DISCUSSION
Increased rigidity of the retinal artery leading to compression of the underlying vein at an arteriovenous crossing site has strongly been implicated in the pathogenesis of BRVO [3]. We hypothesized that BRVO susceptibility might be conferred by functional gene polymorphisms that affected the expression of cytokines or chemokines, which themselves have all been shown to affect atherogenesis. In addition, some cytokines also exert procoagulatory effects and may thus affect BRVO risk by a second mechanism. To improve biologic plausibility gene polymorphisms were only selected as candidate risk factors when these polymorphisms had previously been associated with gene expression or activity of the gene product, and an essential role of the gene product in pro- or anti-inflammatory pathways had been known. Some of these polymorphisms have been associated with cardiovascular diseases, indicating that alterations in the genetics of the inflammatory system may modify the risk of these diseases [77-83].

Neither genotype distributions nor allele frequencies of the investigated gene polymorphisms differed significantly between BRVO patients and control subjects. The statistical power of the present study to detect a potential association between the investigated gene polymorphisms and BRVO was calculated for the polymorphism with the lowest minor allele frequency (IL4−584C>T). For this polymorphism, the present study had a statistical power of 0.80 to detect an odds ratio of ≥1.55, and a statistical power of 0.99 to detect an odds ratio of ≥2.0 for carriers of the mutated allele. For all other polymorphisms, the statistical power was equal or higher than that of the IL4−584C>T polymorphism. Thus, our results strongly suggest that none of these gene variants is likely a major risk factor for BRVO.

The expression of cytokines and chemokines is also affected by factors other than gene polymorphisms [26,49,57,62]. For example, the expression of MCP-1 can be induced by pro-inflammatory cytokines such as IL-1 and TNF-α [57]. Thus, our finding that the investigated gene polymorphisms were not associated with a significantly increased risk for BRVO does not necessarily argue against a role of these cytokines and chemokines in the pathogenesis of BRVO.

Large prospective studies are clearly warranted to elucidate whether altered plasma concentrations of both cytokines and chemokines are predictive for the development of BRVO. This, however, can only be achieved by conducting a prospective instead of a retrospective study. Yet, it is also possible that increased expression of inflammatory mediators may not be detected systemically in blood, but only locally in the vascular wall.

When interpreting the data of the present study, some limitations have to be considered. First, blood samples were

| Risk factor          | Odds ratio | 95% Confidence Interval | p-value |
|----------------------|------------|-------------------------|---------|
| Arterial hypertension| 3.33       | 2.42–4.57               | <0.001  |
| IL1B−511T            | 0.95       | 0.75–1.20               | 0.67    |
| IL1RN 1018C          | 1.18       | 0.94–1.49               | 0.15    |
| IL4−584T             | 0.87       | 0.64–1.18               | 0.37    |
| IL6−174C             | 0.98       | 0.79–1.22               | 0.87    |
| IL10−592A            | 0.83       | 0.65–1.05               | 0.12    |
| IL18 183G            | 0.89       | 0.69–1.16               | 0.39    |
| TNF−308A             | 1.00       | 0.74–1.36               | 0.98    |
| CCL2−2518G           | 1.15       | 0.90–1.48               | 0.27    |
| IL8−251T             | 1.06       | 0.85–1.31               | 0.61    |
| CCL5−403A            | 0.86       | 0.66–1.13               | 0.28    |

Arterial hypertension, but none of the investigated gene polymorphisms, was significantly associated with branch retinal vein occlusion (BRVO) risk.
obtained after the occurrence of BRVO. Thus, the present study is not suitable to investigate plasma cytokine and chemokine patterns. The aim of this study, however, was to investigate a hypothesized association between genetic variants and BRVO risk. As genotypes do not change during a person’s lifetime, the aforementioned limitation does not apply to the analysis of gene polymorphisms. Second, gene variants have been shown to vary between populations of different ethnic origins. Thus, our findings may not necessarily apply to ethnicities other than Caucasian. Finally, genetic studies are designed to compare allele or genotype frequencies between case and control groups. A statistical difference in frequencies between cases and controls suggests that the investigated genetic variant is associated with the disease. In the present candidate gene approach, we selected genetic polymorphisms on the basis of prior knowledge of gene function and allele frequencies. Thus, the candidate gene approach has the advantage of a higher probability of true association, which has been recognized as an important factor influencing the outcome of association studies [84]. The main limitation of the candidate gene approach is the usually low number of polymorphisms investigated. Whole genome association studies, including hundreds of thousands of polymorphisms, are now available. It is likely that results of such studies will provide novel candidates for genetic susceptibility to BRVO.

In conclusion, as none of the investigated gene variants was significantly more prevalent in BRVO patients than among control subjects, our data suggest that these polymorphisms are unlikely major risk factors for BRVO in a Caucasian population.

ACKNOWLEDGMENTS

This study was supported by the Anniversary Fund of the Oesterreichische Nationalbank (Project-Nr. 12245). We thank Ms. Gabriele Trummer, Ms. Christa Wachswender, and Ms. Manuela Fischl for their excellent technical assistance.

REFERENCES

1. Frangieh GT, Green RW, Barraquer-Somers E, Finkelstein D. Histopathologic study of nine branch retinal vein occlusions. Arch Ophthalmol 1982; 100:1132-40. [PMID: 6178389]
2. Zhao J, Sastry SM, Sperduto RD, Chew EY, Remaley NA. Arteriovenous crossing patterns in branch retinal vein occlusion. The Eye Disease Case-Control Study Group. Ophthalmology 1993; 100:423-8. [PMID: 8460014]
3. Fekrat S, Finkelstein D. Venous occlusive disease. In: Regillo CD, Brown GC, Flynn HW Jr, editors. Vitreoretinal disease. The Essentials. New York, Stuttgart: Thieme; 1999. p. 117–32.
4. The Eye Disease Case-control Study Group. Risk factors for branch retinal vein occlusion. Am J Ophthalmol 1993; 116:286-96. [PMID: 8357052]
5. O’Mahoney PR, Wong DT, Ray JG. Retinal vein occlusion and traditional risk factors for atherosclerosis. Arch Ophthalmol 2008; 126:692-9. [PMID: 18474782]
6. Janssen MC, den Heijer M, Cruysberg JR, Wollersheim H, Bredie SJ. Retinal vein occlusion: a form of venous thrombosis or a complication of atherosclerosis? A meta-analysis of thrombophilic factors. Thromb Haemost 2005; 93:1021-6. [PMID: 15968383]
7. Cahill MT, Stinnett SS, Fekrat S. Meta-analysis of plasma homocysteine, serum folate, serum vitamin B(12), and thermolabile MTHFR genotype as risk factors for retinal vascular occlusive disease. Am J Ophthalmol 2003; 136:1136-50. [PMID: 14644226]
8. Ross R. Atherosclerosis – an inflammatory disease. N Engl J Med 1999; 340:115-26. [PMID: 9887164]
9. Frostegard J, Ulfgren AK, Nyberg P, Hedin U, Swedenborg J, Andersson U, Hansson GK. Cytokine expression in advanced human atherosclerotic plaques: dominance of pro-inflammatory (Th1) and macrophage-stimulating cytokines. Atherosclerosis 1999; 145:33-43. [PMID: 10428293]
10. Huber SA, Sakkinen P, Conze D, Hardin N, Tracy R. Interleukin-6 exacerbates early atherosclerosis in mice. Arterioscler Thromb Vasc Biol 1999; 19:2364-7. [PMID: 10521365]
11. Whitman SC, Ravisankar P, Elam H, Daugherty A. Exogenous interferon-gamma enhances atherosclerosis in apolipoprotein E−/− mice. Am J Pathol 2000; 157:1819-24. [PMID: 11106554]
12. Pinderski LJ, Fischbein MP, Subbanagounder G, Fishbein MC, Kuno N, Cheroutre H, Curtiss LK, Berliner JA, Boisvert WA. Overexpression of interleukin-10 by activated T lymphocytes inhibits atherosclerosis in LDL receptor-deficient mice by altering lymphocyte and macrophage phenotypes. Circ Res 2002; 90:1064-71. [PMID: 12093795]
13. Grignani G, Maiolo A. Cytokines and hemostasis. Haematologica 2000; 85:967-72. [PMID: 10980636]
14. van der Poll T, Büller HR, ten Cate H, Wortel CH, Bauer KA, van Deventer SJ, Hack CE, Sauerwein HP, Rosenberg RD, ten Cate JW. Activation of coagulation after administration of tumor necrosis factor to normal subjects. N Engl J Med 1990; 322:1622-7. [PMID: 2188129]
15. Conway EM, Rosenberg RD. Tumor necrosis factor suppresses transcription of the thrombomodulin gene in endothelial cells. Mol Cell Biol 1988; 8:5588-92. [PMID: 2854203]
16. Fox EA, Kahn SR. The relationship between inflammation and venous thrombosis. A systematic review of clinical studies. Thromb Haemost 2005; 94:362-5. [PMID: 16113826]
17. Stouthard JM, Levi M, Hack CE, Veenhof CH, Romijn HA, Sauerwein HP, van der Poll T. Interleukin-6 stimulates coagulation, not fibrinolysis, in humans. Thromb Haemost 1996; 76:738-42. [PMID: 8950783]
18. Dinarello CA. Biologic basis for interleukin-1 in disease. Blood 1988; 78:2015-47. [PMID: 8630372]
19. Young JL, Libby P, Schönbeck U. Cytokines in the pathogenesis of atherosclerosis. Thromb Haemost 2002; 88:554-67. [PMID: 12362224]
20. Kirii H, Niwa T, Yamada Y, Wada H, Saito K, Iwakura Y, Asano M, Moriwaki H, Seishima M. Lack of interleukin-1 beta decreases the severity of atherosclerosis in ApoE-deficient mice. Arterioscler Thromb Vasc Biol 2003; 23:656-60. [PMID: 12615675]
regulating low-density lipoprotein receptor-related protein in AML 12 cells. Biochem Biophys Res Commun 2001; 288:42-8. [PMID: 11594749]

22. Iacoviello L, Di Castelnuovo A, Gattone M, Pezzini A, Assanelli D, Lorenzetti D, Del Zotto E, Colombo M, Napoleon E, Amore C, D’Orazio A, Padovani A, de Gaetano G, Giannuzzi P, Donati MB. IGIIG Investigators. Polymorphisms of the interleukin-1beta gene affect the risk of myocardial infarction and ischemic stroke at young age and the response of mononuclear cells to stimulation in vitro. Arterioscler Thromb Vasc Biol 2005; 25:222-7. [PMID: 15536296]

23. Devlin CM, Kuriakose G, Hirsch E, Tabas I. Genetic alterations of IL-1 receptor antagonist in mice affect plasma cholesterol level and foam cell lesion size. Proc Natl Acad Sci USA 2002; 99:6280-5. [PMID: 11983917]

24. Isoda K, Sawada S, Ishigami N, Matsuki T, Miyazaki K, Kusuhara M, Iwakura Y, Ohzuzu F. Lack of interleukin-1 receptor antagonist modulates platelet composition in apolipoprotein E-deficient mice. Arterioscler Thromb Vasc Biol 2004; 24:1068-73. [PMID: 15059807]

25. Reiner AP, Wurfel MM, Lange LA, Carlson CS, Nord AS, Carty CL, Rieder MJ, Desmarais C, Jenny NS, Iribarren C, Hoffmann SC, Stanley EM, Darrin Cox E, Craighead N, Moore KW, O’Garra A. IL-10 acts on the antigen-presenting cell to inhibit cytokine production by Th1 cells. J Immunol 2001; 167:1117-25. [PMID: 12937153]

26. King VL, Szilvassy SJ, Daugherty A. Interleukin-4 deficiency decreases atherosclerotic lesion formation in a site-specific manner in female LDL receptor −/− mice. Arterioscler Thromb Vasc Biol 2002; 22:456-61. [PMID: 11884290]

27. Barks JL, McQuillan JJ, Iademarco MF. TNF-alpha and IL-4 synergistically increase vascular cell adhesion molecule-1 expression in cultured vascular smooth muscle cells. J Immunol 1997; 159:4532-8. [PMID: 9379054]

28. Conrad DJ, Kuhn H, Mulkins M, Highland E, Sigal E. Specific inflammatory cytokines regulate the expression of human monocyte 15-lipoxygenase. Proc Natl Acad Sci USA 1992; 89:217-21. [PMID: 1729692]

29. Walch L, Massade L, Dufilho M, Bussolino F, Poli V, Ciliberto G, Mantovani A. Role of IL-6 and its soluble receptor in induction of chemokines and leukocyte recruitment. Immunity 1997; 6:315-25. [PMID: 9075932]

30. Davenport P, Tipping PG. The role of interleukin-4 and its soluble receptor in induction of chemokines and leukocyte recruitment. Immunology 1997; 6:315-25. [PMID: 9075932]

31. Neumann FJ, Ott I, Marx N, Luther T, Kennegott S, Gawaz M, Kotsch M, Schömig A. Effect of human recombinant interleukin-6 and interleukin-8 on monocyte procoagulant activity. Arterioscler Thromb Vasc Biol 1997; 17:3399-405. [PMID: 9437185]

32. Rosenwasser LJ, Borish L. Promoter polymorphisms predisposing to the development of asthma and atopy. Clin Exp Allergy 1998; 28:13-5. [PMID: 9988441]

33. Van Snick J. Interleukin-6: an overview. Annu Rev Immunol 1990; 8:253-78. [PMID: 21886644]

34. Romano M, Sironi M, Toniatti C, Polentarutti N, Fruscello P, Ghezzi P, Faggioni R, Luini W, van Hinsbergh V, Sozzani S, Bussolino F, Poli V, Ciliberto G, Mantovani A. Role of IL-6 and its soluble receptor in induction of chemokines and leukocyte recruitment. Immunity 1997; 6:315-25. [PMID: 9075932]

35. Romano M, Sironi M, Toniatti C, Polentarutti N, Fruscello P, Ghezzi P, Faggioni R, Luini W, van Hinsbergh V, Sozzani S, Bussolino F, Poli V, Ciliberto G, Mantovani A. Role of IL-6 and its soluble receptor in induction of chemokines and leukocyte recruitment. Immunity 1997; 6:315-25. [PMID: 9075932]
hematopoietic-cell transplantation. N Engl J Med 2003; 349:2201-10. [PMID: 14657427]
48. Weger M, Steinbrugger I, El-Shabrawi Y, Wegscheider BJ, Weger W, Renner W, Schmut O, Haas A. Haplotypetagging interleukin-10 promoter polymorphism is associated with reduced risk of retinal artery occlusion. Mol Vis 2007; 13:549-52. [PMID: 17438520]
49. Puren AJ, Fantuzzi G, Gu Y, Su MS, Dinarello CA. Interleukin-18 (IFNgamma-inducing factor) induces IL-8 and IL-1beta via TNFalpha production from non-CD14+ human blood mononuclear cells. J Clin Invest 1998; 101:711-21. [PMID: 9449707]
50. Elhage R, Jawien J, Rudling M, Ljunggren HG, Takeda K, Akira S, Bayard F, Hansson GK. Reduced atherosclerosis in interleukin-18 deficient apolipoprotein E-knockout mice. Cardiovasc Res 2003; 59:234-40. [PMID: 12829194]
51. Whitman SC, Ravisankar P, Daugherty A. Interleukin-18 gene in cardiovascular disease. Circulation 2005; 107:304-8. [PMID: 15670907]
52. Tiret L, Godefroy T, Lubos E, Nicaud V, Tregouet DA, Barbaux S, Schnabel R, Bickel C, Hansson GK. Reduced atherosclerosis in interleukin-18 deficient apolipoprotein E-knockout mice. J Clin Invest 1998; 101:711-21. [PMID: 9449707]
53. Vassalli P. The pathophysiology of tumor necrosis factors. Annu Rev Immunol 1992; 10:411-52. [PMID: 1590993]
54. Ohta H, Wada H, Niwa T, Kirihi H, Iwamoto N, Fujii H, Saito S, Akira S, Bayard F, Hansson GK. Reduced atherosclerosis in interleukin-18 deficient apolipoprotein E-knockout mice. J Mol Med 2003; 81:643-50. [PMID: 16043644]
55. Vassalli P. The pathophysiology of tumor necrosis factors. Annu Rev Immunol 1992; 10:411-52. [PMID: 1590993]
56. Louis R, Belaiche J. Tumor necrosis factor (TNF) gene polymorphism influences TNF-alpha production in non-CD14+ human blood mononuclear cells. J Mol Med 1998; 101:711-21. [PMID: 9449707]
57. Sica A, Wang JM, Colotta F, Dejana E, Mantovani A, Oppenheim JJ, Larsen CG, Zachariae CO, Matsushima K. Monocyte chemotactic and activating factor gene expression induced in endothelial cells by IL-1 and tumour necrosis factor. J Immunol 1990; 144:3034-8. [PMID: 2182712]
58. Boring L, Gosling J, Cleary M, Charo IF. Decreased lesion formation in CCR2 −/− mice reveals a role for chemokines in the initiation of atherosclerosis. Nature 1998; 394:894-7. [PMID: 9732872]
59. Aiello RJ, Bourassa PA, Lindsey S, Weng W, Natoli E, Rollins BJ, Milos PM. Monocyte chemotactrant protein-1 accelerates atherosclerosis in apolipoprotein E-deficient mice. Arterioscler Thromb Vasc Biol 1999; 19:1518-25. [PMID: 10364084]
60. Schecter AD, Rollins BJ, Zhang YJ, Charo IF, Fallon JT, Rossikhina M, Giesen PL, Nemerson Y, Taubman MB. Tissue factor is induced by monocyte chemotactrant protein-1 in human aortic smooth muscle and THP-1 cells. J Biol Chem 1997; 272:28568-73. [PMID: 9353321]
61. Rovin BH, Lu L, Saxena R. A novel polymorphism in the MCP-1 gene regulatory region that influences MCP-1 expression. Biochem Biophys Res Commun 1999; 259:344-8. [PMID: 10362511]
62. Kaplanski G, Farnarier C, Kaplanski S, Porat R, Shapiro L, Bongrand P, Dinarello CA. Interleukin-1 induces interleukin-8 secretion from endothelial cells by a juxtaacrine mechanism. Blood 1998; 84:4242-8. [PMID: 7994038]
63. Gerszten RE, Garcia-Zepeda EA, Lim YC, Yoshida M, Ding HA, Gimbrone MA Jr, Luster AD, Luscinfskas FW, Rosenzweig A. MCP-1 and IL-8 trigger firm adhesion of monocytes to vascular endothelium under flow conditions. Nature 1999; 398:718-23. [PMID: 10227295]
64. Boisvert WA, Santiago R, Curtiss LK, Terceltauba RA. A leuokcytome homologue of the IL-8 receptor CXCR-2 mediates the accumulation of macrophages in atherosclerotic lesions of LDL receptor-deficient mice. J Clin Invest 1998; 101:353-63. [PMID: 9435307]
65. Hull J, Thomson A, Kwiatkowski D. Association of respiratory syncytial virus bronchiolitis with the interleukin 8 gene region in UK families. Thorax 2000; 55:1023-7. [PMID: 11083887]
66. Lee WP, Tai DI, Lan KH, Li AF, Hsu HC, Lin EJ, Lin YP, Sheu ML, Li CP, Chang FY, Chao Y, Shen SH, Lee SD. The −251T allele of the interleukin-8 promoter is associated with increased risk of gastric carcinoma featuring diffuse-type histopathology in Chinese population. Clin Cancer Res 2005; 11:6431-41. [PMID: 16166417]
67. von Hundelshausen P, Weber KS, Huo Y, Proudfoot AE, Nelson PJ, Ley K, Weber C. RANTES deposition by platelets triggers monocyte arrest on inflamed and atherosclerotic endothelium. Circulation 2001; 103:1772-7. [PMID: 11282909]
68. Wilcox JN, Nelken NA, Coughlin SR, Gordon D, Schall TJ. Local expression of inflammatory cytokines in human atherosclerotic plaques. J Atheroscler Thromb 1994;S10-3. [PMID: 9228884]
69. Veillard NR, Kwak B, Pelli G, Mulhaupt F, James RW, Proudfoot AE, Mach F. Antagonism of RANTES receptors reduces atherosclerotic plaque formation in mice. Circ Res 2004; 94:253-61. [PMID: 14656931]
70. Nickel RG, Casolaro V, Wahl U, Beyer K, Barnes KC, Plunkett BS, Freidhoff LR, Sengler C, Plitt JR, Schleimer RP, Caraballo L, Naidu RP, Levett PN, Beatty TH, Huang SK. Atopic dermatitis is associated with a functional mutation in the promoter of the C–C chemokine RANTES. J Immunol 2000; 164:1612-6. [PMID: 10640782]
71. Rockman MV, Hahn MW, Soranzo N, Goldstein DB, Wray GA. Positive selection on a human-specific transcription factor binding site regulating IL4 expression. Curr Biol 2003; 13:2118-23. [PMID: 14654003]
72. Nauck M, Winkelmann BR, Hoffmann MM, Böhm BO, Wieland H, März W. The interleukin-6 G(−174)C promoter polymorphism in the LURIC cohort: no association with
plasma interleukin-6, coronary artery disease, and myocardial infarction. J Mol Med 2002; 80:507-13. [PMID: 12185451]

73. Langsenlehner U, Kripp B, Renner W, Yazdani-Biuki B, Eder T, Köppel H, Wascher TC, Paulweber B, Samonigg H. Interleukin-10 promoter polymorphism is associated with decreased breast cancer risk. Breast Cancer Res Treat 2005; 90:113-5. [PMID: 15803357]

74. El-Shabrawi Y, Wegscheider BJ, Weger M, Renner W, Posch U, Ulrich S, Ardjomand N, Hermann J. Polymorphisms within the tumor necrosis factor-alpha promoter region in patients with HLA-B27 associated uveitis: association with susceptibility and clinical manifestations. Ophthalmology 2006; 113:695-700. [PMID: 16581430]

75. Wegscheider BJ, Weger M, Renner W, Posch U, Ulrich S, Hermann J, Ardjomand N, Haller-Schober EM, El-Shabrawi Y. Role of the CCL2/MCP-1 −2518A>G gene polymorphism in HLA-B27 associated uveitis. Mol Vis 2005; 11:896-900. [PMID: 16280979]

76. Goverdhan SV, Ennis S, Hannan SR, Madhusudhana KC, Cree AJ, Luff AJ, Lotery AJ. Interleukin-8 promoter polymorphism −251A/T is a risk factor for age-related macular degeneration. Br J Ophthalmol 2008; 92:537-40. [PMID: 18310311]

77. Simeoni E, Winkelmann BR, Hoffmann MM, Fleury S, Ruiz J, Kappenberger L, März W, Vassalli G. Association of RANTES G−403A gene polymorphism with increased risk of coronary atherosclerosis. Eur Heart J 2004; 25:1438-46. [PMID: 15302103]

78. Andreotti F, Porto I, Crea F, Maseri A. Inflammatory gene polymorphisms and ischemic heart disease: review of population association studies. Heart 2002; 87:107-12. [PMID: 11796541]

79. Vendrell J, Fernandez-Real JM, Gutierrez C, Zamora A, Simon I, Barajai A, Ricart W, Richart C. A polymorphism in the promoter region of the tumor necrosis factor-alpha gene (−308) is associated with coronary heart disease in type 2 diabetic patients. Atherosclerosis 2003; 167:257-64. [PMID: 12818408]

80. Bernard V, Pillois X, Dubus I, Benchimol D, Labouyrie JP, Couffinhal T, Coste P, Bonnet J. The −308 G/A tumor necrosis factor-alpha gene dimorphism: a risk factor for unstable angina. Clin Chem Lab Med 2003; 41:511-6. [PMID: 12747595]

81. Sbarsi I, Falcone C, Boiocchi C, Campo I, Zorzetto M, De Silvestri A, Cuccia M. Inflammation and atherosclerosis: the role of TNF and TNF receptors polymorphisms in coronary artery disease. Int J Immunopathol Pharmacol 2007; 20:145-54. [PMID: 17346438]

82. Jang Y, Chae JS, Hyun YJ, Koh SJ, Ko MJ, Rim SJ, Shin HJ, Ordovas JM, Lee JH. The RANTES −403G>A promoter polymorphism in Korean men: association with serum RANTES concentrations and coronary artery disease. Clin Sci (Lond) 2007; 113:349-56. [PMID: 17504241]

83. Rundek T, Elkind MS, Pittman J, Boden-Albala B, Martin S, Humphries SE, Joo SH, Sacco RL. Carotid intima-media thickness is associated with allelic variants of stromelysin-1, interleukin-6, and hepatic lipase genes: the Northern Manhattan Prospective Cohort Study. Stroke 2002; 33:1420-3. [PMID: 11988625]

84. Ioannidis JP. Why most published research findings are false. PLoS Med 2005; 2:e124. [PMID: 16060722]